UNIGE document Scientific Article
previous document  unige:25168  next document
add to browser collection
Title

High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus

Authors
Ferry, Tristan
show hidden authors show all authors [1 - 11]
Published in Antimicrobial Agents and Chemotherapy. 2012, vol. 56, no. 3, p. 1258-64
Abstract Reduced susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates is considered a risk factor for failure of glycopeptide therapy. We compared the prevalences of MRSA isolates with reduced glycopeptide susceptibility in patients with versus without persistent or recurrent MRSA bloodstream infections. A retrospective cohort study at the University Hospital of Geneva identified 27 patients with persistent or recurrent clonally related MRSA bacteremic episodes over an 8-year period, which included 208 consecutive nosocomial MRSA bacteremic episodes. Vancomycin and teicoplanin MICs were determined by a modified macrodilution assay allowing improved detection of glycopeptide-intermediate MRSA isolates (GISA), characterized by elevated teicoplanin or/and vancomycin MICs (≥ 4 μg/ml). For 16 patients (59%), their pretherapy and/or posttherapy MRSA isolates showed elevated teicoplanin MICs, among which 10 (37%) concomitantly displayed elevated vancomycin MICs. In contrast, 11 other patients (41%) were persistently or recurrently infected with non-GISA isolates. In comparison, only 39 (22%) of 181 single isolates from patients with no microbiological evidence of persistent or recurrent infections showed elevated teicoplanin MICs, among which 14 (8%) concomitantly displayed elevated vancomycin MICs. Clinical, microbiological, and pharmacokinetic variables for patients persistently or recurrently infected with GISA or non-GISA isolates were similar. Bacteremic patients with a poor response to glycopeptide therapy had a 2.8-fold- and 4.8-fold-higher rates of MRSA isolates displaying elevated teicoplanin and vancomycin MICs, respectively, than patients with single isolates (P < 0.0001). Detection of elevated teicoplanin MICs may help to predict a poor response to glycopeptide therapy in MRSA bacteremic patients.
Keywords AgedAged, 80 and overAnti-Bacterial Agents/pharmacology/therapeutic useBacteremia/drug therapy/microbiologyChild, PreschoolDrug Resistance, Bacterial/drug effectsFemaleHumansMaleMethicillin-Resistant Staphylococcus aureus/drug effects/growth & development/isolation & purificationMicrobial Sensitivity TestsMiddle AgedRecurrenceRetrospective StudiesStaphylococcal Infections/drug therapy/microbiologyTeicoplanin/pharmacology/therapeutic useVancomycin/pharmacology/therapeutic use
Identifiers
PMID: 22155824
Full text
Article (Published version) (168 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research groups Analyse génomique et fonctionnelle du staphylocoque doré (604)
Glycopeptide résistance (28)
Groupe Harbarth Stephan (Staphylocoques dorés résistants à la méthicilline) (866)
Citation
(ISO format)
UCKAY, Ilker et al. High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus. In: Antimicrobial Agents and Chemotherapy, 2012, vol. 56, n° 3, p. 1258-64. https://archive-ouverte.unige.ch/unige:25168

127 hits

0 download

Update

Deposited on : 2013-01-09

Export document
Format :
Citation style :